Please assess the completion status of the following clinical trial:

Trial Title: Subclinical Cardiovascular Disease in Psoriatic Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a history of moderate to severe psoriatic disease~* Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease~Exclusion Criteria:~* Unable to speak Spanish or English~* Active smoking (within the past year)~* Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis~* Known active cancer receiving treatment~* Pregnancy~* Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600)~* A history of severe bleeding or bleeding disorders~* Current medication use which interact with either aspirin or atorvastatin~* Chronic kidney disease (CrCl \< 30ml/min)~* Congestive heart failure~* Currently taking aspirin or a statin.~* NSAID use within the past 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Psoriatic Disease Patients (Type: OTHER): Moderate to severe psoriatic disease
- Healthy Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).